NEW YORK (TheStreet) –– IBM (IBM) continues to push the boundaries of its Watson Group, announcing an investment in Pathway Genomics, a clinical laboratory that offers genetic testing services globally, to help deliver an health-monitoring app based on a person's individual genetic makeup and other personal information.
San Diego-based Pathway has now raised more than $80 million over the past six years, and the investment from IBM Watson will allow it to expand further into the bioinformatics market, which is expected to grow to $12.86 billion by 2020, according to Allied Market Research. "By tapping into IBM Watson's cognitive computing capabilities, Pathway Genomics is allowing consumers to ask health related questions, in their own words and receive personalized and relevant responses," said Stephen Gold, Vice President, IBM Watson Group in a press release. "Cognitive computing solutions based on Watson's transformative technology will help define how consumers and businesses alike make better informed lifestyle decisions, enabling better outcomes."
Terms of the investment were not disclosed.
The app, which will utilize Watson's computing prowess, will allow consumers to ask the app questions and get answers based on their genes, information from wearable technology and other information, including their emotional, physical and social well being. Questions asked can include, "How much exercise should I should today?" or "How much coffee can I drink on Monday?"
In January, IBM announced it would be investing $1 billion on the Watson Group, with much of it focused on R&D and bringing cloud-based applications and services to market. As part of that $1 billion, $100 million will go towards investing in startups, such as Pathway, and businesses building Watson-powered apps.